Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessJazz Pharmaceuticals' Financial and Operational Highlights

Jazz Pharmaceuticals’ Financial and Operational Highlights

Add to Favorite
Added to Favorite


Earnings per Share (EPS) of $3.40, missing the estimated $5.50.
Third-quarter revenue of $1.05 billion, a 14% increase year-over-year, surpassing expectations.
Advancing product pipeline with a PDUFA date for Zanidatamab and plans for a supplemental New Drug Application for Zepzelca.

Jazz Pharmaceuticals, listed as NASDAQ:JAZZ, is a biopharmaceutical company known for its focus on developing and commercializing innovative medicines. The company specializes in therapies for sleep disorders, oncology, and other areas. Despite reporting an earnings per share (EPS) of $3.40, which fell short of the estimated $5.50, Jazz’s revenue reached approximately $1.05 billion, surpassing the expected $1.04 billion.

The company’s third-quarter revenue of $1.05 billion represents a 14% increase from the previous year, driven by strong sales of key therapies like Xywav, Epidiolex, and Rylaze. Jazz’s gross margin remains robust at 89%, indicating efficient cost management. CEO Bruce Cozadd is confident in achieving the company’s revenue guidance of $4.0 to $4.1 billion for the full year, as highlighted by Benzinga.

Jazz Pharmaceuticals is also advancing its product pipeline, with a PDUFA date set for November 29, 2024, for Zanidatamab, targeting second-line biliary tract cancer. The company plans to submit a supplemental New Drug Application for Zepzelca in the first-line treatment of extensive-stage small cell lung cancer in the first half of 2025. These developments reflect Jazz’s strategic focus on expanding its oncology portfolio.

Financially, Jazz holds $2.6 billion in cash and investments, with $500 million in undrawn credit facilities, positioning it well for future growth. Despite concerns about its debt levels, the company maintains a debt-to-equity ratio of approximately 1.48, indicating a balanced approach to leveraging. The current ratio of around 4.26 showcases Jazz’s ability to cover short-term liabilities with its short-term assets.

Jazz’s market valuation metrics include a price-to-earnings (P/E) ratio of approximately 14.79 and a price-to-sales ratio of about 1.73. The enterprise value to sales ratio is around 2.72, while the enterprise value to operating cash flow ratio is approximately 9.32. These figures provide insight into how the market values Jazz’s sales and cash flow relative to its overall valuation.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Arch Capital Group’s Market Outlook and Financial Performance

Michael Zaremski from Capital One Financial set a price...

Clarivate Plc (NYSE:CLVT) Q3 Earnings Overview

Clarivate Plc reported a Q3 EPS of -$0.09128, missing...

Clean Energy Fuels Corp. (NASDAQ: CLNE) Financial Performance Review

Clean Energy Fuels Corp. (NASDAQ:CLNE) reported a revenue of...

Ashland Inc. (NYSE:ASH) Quarterly Earnings Overview

Ashland Inc. (NYSE:ASH) reported a revenue of $522 million,...